Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
1 "Consensus"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Review
Metabolic Risk/Epidemiology
Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus
Jinyoung Kim, Hyuk-Sang Kwon
Diabetes Metab J. 2022;46(2):165-180.   Published online March 24, 2022
DOI: https://doi.org/10.4093/dmj.2021.0377
  • 8,681 View
  • 508 Download
  • 11 Web of Science
  • 10 Crossref
AbstractAbstract PDFPubReader   ePub   
A durable normoglycemic state was observed in several studies that treated type 2 diabetes mellitus (T2DM) patients through metabolic surgery, intensive therapeutic intervention, or significant lifestyle modification, and it was confirmed that the functional β-cell mass was also restored to a normal level. Therefore, expert consensus introduced the concept of remission as a common term to express this phenomenon in 2009. Throughout this article, we introduce the recently updated consensus statement on the remission of T2DM in 2021 and share our perspective on the remission of diabetes. There is a need for more research on remission in Korea as well as in Western countries. Remission appears to be prompted by proactive treatment for hyperglycemia and significant weight loss prior to irreversible β-cell changes. T2DM is not a diagnosis for vulnerable individuals to helplessly accept. We attempt to explain how remission of T2DM can be achieved through a personalized approach. It may be necessary to change the concept of T2DM towards that of an urgent condition that requires rapid intervention rather than a chronic, progressive disease. We must grasp this paradigm shift in our understanding of T2DM for the benefit of our patients as endocrine experts.

Citations

Citations to this article as recorded by  
  • Weight change in patients with new‐onset type 2 diabetes mellitus and its association with remission: Comprehensive real‐world data
    Jinyoung Kim, Bongseong Kim, Mee Kyoung Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon
    Diabetes, Obesity and Metabolism.2024; 26(2): 567.     CrossRef
  • Mechanisms and the strategy for remission of type 2 diabetes mellitus
    Tien‐Jyun Chang
    Journal of Diabetes Investigation.2023; 14(3): 351.     CrossRef
  • Remission of type 2 diabetes: A critical appraisal
    Michele Ricci, Juan José Mancebo-Sevilla, Lidia Cobos Palacios, Jaime Sanz-Cánovas, Almudena López-Sampalo, Halbert Hernández-Negrin, Miguel Angel Pérez-Velasco, Luis M. Pérez-Belmonte, Maria Rosa Bernal-López, Ricardo Gómez-Huelgas
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Incidence and predictors of remission and relapse of type 2 diabetes mellitus in Japan: Analysis of a nationwide patient registry (JDDM73)
    Kazuya Fujihara, Laymon Khin, Koshiro Murai, Yurie Yamazaki, Kahori Tsuruoka, Noriko Yagyuda, Katsuya Yamazaki, Hiroshi Maegawa, Shiro Tanaka, Satoru Kodama, Hirohito Sone
    Diabetes, Obesity and Metabolism.2023; 25(8): 2227.     CrossRef
  • Use of SGLT2 inhibitors after bariatric/metabolic surgery: Risk/benefit balance
    André J. Scheen
    Diabetes & Metabolism.2023; 49(4): 101453.     CrossRef
  • Cardiovascular Risk Reduction in Type 2 Diabetes: Further Insights into the Power of Weight Loss and Exercise
    Seung-Hwan Lee
    Endocrinology and Metabolism.2023; 38(3): 302.     CrossRef
  • Unlocking the Potential of Type 2 Diabetes Mellitus Remission
    Prakriti Sharma, Swarupa Chakole
    Cureus.2023;[Epub]     CrossRef
  • Global research trends of diabetes remission: a bibliometric study
    Xue Yang, Zhiwei He, Qilin Chen, Yu Chen, Guofang Chen, Chao Liu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis
    Keke Tong, Shuang Yin, Yunfeng Yu, Xinyu Yang, Gang Hu, Fei Zhang, Zhenjie Liu
    Medicine.2023; 102(43): e35488.     CrossRef
  • Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
    Yunfeng Yu, Gang Hu, Shuang Yin, Xinyu Yang, Manli Zhou, Weixiong Jian
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal